Laboratory Medicine ›› 2019, Vol. 34 ›› Issue (12): 1066-1071.DOI: 10.3969/j.issn.1673-8640.2019.12.002
Previous Articles Next Articles
CHEN Shiyang1, FU Xiaoying1, XU Gang1, LIN Zhenhu1, LUO Meizhu1, MAI Huirong2, CHEN Yunsheng1, LIU Sixi2
Received:
2018-08-22
Online:
2019-12-30
Published:
2020-01-03
CLC Number:
CHEN Shiyang, FU Xiaoying, XU Gang, LIN Zhenhu, LUO Meizhu, MAI Huirong, CHEN Yunsheng, LIU Sixi. Monitoring lymphocyte subsets after β-mediterranean anemia allogeneic hematopoetic stem cell transplantation in children[J]. Laboratory Medicine, 2019, 34(12): 1066-1071.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2019.12.002
时间点 | 例数 | CD3+ T细胞 | CD3+CD4+ T细胞 | CD3+CD8+ T细胞 | CD4+/CD8+ 比值 | CD19+ B细胞 | CD16+CD56+ NK细胞 |
---|---|---|---|---|---|---|---|
术前 | 27 | 69.31±11.74 | 37.53±8.88 | 27.44±11.43 | 1.42(1.16~1.96) | 18.30(11.50~21.88) | 12.30±6.94 |
术后第1个月 | 27 | 71.44±7.97 | 14.62±8.58** | 52.78±19.93** | 0.28(0.15~0.42)** | 2.17(0.54~20.34)** | 17.48±9.53* |
术后第2个月 | 27 | 56.75±16.79** | 11.53±5.58** | 41.65±15.50** | 0.24(0.16~0.43)** | 16.99(4.57~28.60) | 22.81±10.68** |
术后第3个月 | 27 | 54.26±17.16** | 12.46±4.92** | 36.14±15.16** | 0.30(0.24~0.44)** | 18.00(8.50~42.70) | 20.50±8.14** |
术后第6个月 | 27 | 54.10±14.39** | 16.06±5.95** | 34.61±14.04* | 0.44(0.30~0.83)** | 30.20(10.45~36.03)** | 17.57±7.48** |
术后第12个月 | 27 | 60.89±11.58** | 22.49±6.16** | 34.93±12.47* | 0.71(0.46~1.00)** | 23.10(15.50~32.93)* | 13.74±6.06 |
统计值 | 7.030 | 39.885 | 6.500 | 68.418 | 31.699 | 6.326 | |
P值 | 0.001 | <0.001 | 0.001 | <0.001 | <0.001 | 0.002 |
时间点 | 例数 | CD3+ T细胞 | CD3+CD4+ T细胞 | CD3+CD8+ T细胞 | CD4+/CD8+ 比值 | CD19+ B细胞 | CD16+CD56+ NK细胞 |
---|---|---|---|---|---|---|---|
术前 | 27 | 69.31±11.74 | 37.53±8.88 | 27.44±11.43 | 1.42(1.16~1.96) | 18.30(11.50~21.88) | 12.30±6.94 |
术后第1个月 | 27 | 71.44±7.97 | 14.62±8.58** | 52.78±19.93** | 0.28(0.15~0.42)** | 2.17(0.54~20.34)** | 17.48±9.53* |
术后第2个月 | 27 | 56.75±16.79** | 11.53±5.58** | 41.65±15.50** | 0.24(0.16~0.43)** | 16.99(4.57~28.60) | 22.81±10.68** |
术后第3个月 | 27 | 54.26±17.16** | 12.46±4.92** | 36.14±15.16** | 0.30(0.24~0.44)** | 18.00(8.50~42.70) | 20.50±8.14** |
术后第6个月 | 27 | 54.10±14.39** | 16.06±5.95** | 34.61±14.04* | 0.44(0.30~0.83)** | 30.20(10.45~36.03)** | 17.57±7.48** |
术后第12个月 | 27 | 60.89±11.58** | 22.49±6.16** | 34.93±12.47* | 0.71(0.46~1.00)** | 23.10(15.50~32.93)* | 13.74±6.06 |
统计值 | 7.030 | 39.885 | 6.500 | 68.418 | 31.699 | 6.326 | |
P值 | 0.001 | <0.001 | 0.001 | <0.001 | <0.001 | 0.002 |
组别 | 例数 | CD3+ T细胞 | CD3+CD4+ T细胞 | CD3+CD8+ T细胞 | CD4+/CD8+ 比值 | CD19+ B细胞 | CD16+CD56+ NK细胞 |
---|---|---|---|---|---|---|---|
术前 | |||||||
HLA全相合 | 20 | 66.78±11.45 | 36.48±9.94 | 26.21±12.68 | 1.49(1.17~2.14) | 19.05(11.05~25.24) | 13.19±7.39 |
HLA不全相合 | 7 | 76.55±9.94 | 40.54±3.85 | 30.94±6.16 | 1.36(1.16~1.54) | 15.22(11.50~18.34) | 9.75±5.05 |
术后 | |||||||
第1个月 | |||||||
HLA全相合 | 20 | 69.34±18.37 | 15.18±8.59 | 49.38±20.17 | 0.27(0.16~0.61) | 2.92(0.56~26.07) | 18.40±9.78 |
HLA不全相合 | 7 | 77.02±17.11 | 13.12±9.18 | 61.85±17.64 | 0.28(0.05~0.38) | 1.17(0.46~20.35) | 15.00±9.18 |
组别 | 例数 | CD3+ T细胞 | CD3+CD4+ T细胞 | CD3+CD8+ T细胞 | CD4+/CD8+ 比值 | CD19+ B细胞 | CD16+CD56+ NK细胞 |
第2个月 | |||||||
HLA全相合 | 20 | 55.87±16.05 | 12.23±6.10 | 39.68±14.45 | 0.26(0.18~0.44) | 17.70(4.83~32.92) | 22.88±11.16 |
HLA不全相合 | 7 | 59.26±19.89 | 9.53±3.30 | 47.27±18.15 | 0.22(0.11~0.43) | 15.88(0.60~22.90) | 22.59±9.98 |
第3个月 | |||||||
HLA全相合 | 20 | 55.52±15.54 | 12.77±5.45 | 35.89±13.87 | 0.28(0.24~0.44) | 17.59(6.61~36.04) | 21.09±8.64 |
HLA不全相合 | 7 | 50.65±22.13 | 11.53±3.06 | 36.83±19.63 | 0.33(0.18~0.67) | 29.14(8.50~53.22) | 18.80±6.80 |
第6个月 | |||||||
HLA全相合 | 20 | 54.26±12.31 | 17.04±6.20 | 33.32±11.85 | 0.46(0.33~0.90) | 30.03(17.88~35.96) | 17.33±7.41 |
HLA不全相合 | 7 | 53.62±20.42 | 13.23±4.36 | 38.28±19.71 | 0.31(0.24~0.81) | 31.42(7.44~38.48) | 18.25±8.23 |
第12个月 | |||||||
HLA全相合 | 20 | 57.76±9.76 | 21.92±5.42 | 31.99±10.05 | 0.72(0.53~0.95) | 27.14(20.29~36.07) | 13.70±6.57 |
HLA不全相合 | 7 | 69.82±12.37 | 24.10±8.21 | 43.34±15.58 | 0.46(0.30~1.14) | 11.62(7.33~25.24) | 13.86±4.76 |
统计值 | 0.004 | 0.958 | 0.084 | 60.000 | 35.000 | 1.017 | |
P值 | 0.948 | 0.330 | 0.772 | 0.580 | 0.053 | 0.316 |
组别 | 例数 | CD3+ T细胞 | CD3+CD4+ T细胞 | CD3+CD8+ T细胞 | CD4+/CD8+ 比值 | CD19+ B细胞 | CD16+CD56+ NK细胞 |
---|---|---|---|---|---|---|---|
术前 | |||||||
HLA全相合 | 20 | 66.78±11.45 | 36.48±9.94 | 26.21±12.68 | 1.49(1.17~2.14) | 19.05(11.05~25.24) | 13.19±7.39 |
HLA不全相合 | 7 | 76.55±9.94 | 40.54±3.85 | 30.94±6.16 | 1.36(1.16~1.54) | 15.22(11.50~18.34) | 9.75±5.05 |
术后 | |||||||
第1个月 | |||||||
HLA全相合 | 20 | 69.34±18.37 | 15.18±8.59 | 49.38±20.17 | 0.27(0.16~0.61) | 2.92(0.56~26.07) | 18.40±9.78 |
HLA不全相合 | 7 | 77.02±17.11 | 13.12±9.18 | 61.85±17.64 | 0.28(0.05~0.38) | 1.17(0.46~20.35) | 15.00±9.18 |
组别 | 例数 | CD3+ T细胞 | CD3+CD4+ T细胞 | CD3+CD8+ T细胞 | CD4+/CD8+ 比值 | CD19+ B细胞 | CD16+CD56+ NK细胞 |
第2个月 | |||||||
HLA全相合 | 20 | 55.87±16.05 | 12.23±6.10 | 39.68±14.45 | 0.26(0.18~0.44) | 17.70(4.83~32.92) | 22.88±11.16 |
HLA不全相合 | 7 | 59.26±19.89 | 9.53±3.30 | 47.27±18.15 | 0.22(0.11~0.43) | 15.88(0.60~22.90) | 22.59±9.98 |
第3个月 | |||||||
HLA全相合 | 20 | 55.52±15.54 | 12.77±5.45 | 35.89±13.87 | 0.28(0.24~0.44) | 17.59(6.61~36.04) | 21.09±8.64 |
HLA不全相合 | 7 | 50.65±22.13 | 11.53±3.06 | 36.83±19.63 | 0.33(0.18~0.67) | 29.14(8.50~53.22) | 18.80±6.80 |
第6个月 | |||||||
HLA全相合 | 20 | 54.26±12.31 | 17.04±6.20 | 33.32±11.85 | 0.46(0.33~0.90) | 30.03(17.88~35.96) | 17.33±7.41 |
HLA不全相合 | 7 | 53.62±20.42 | 13.23±4.36 | 38.28±19.71 | 0.31(0.24~0.81) | 31.42(7.44~38.48) | 18.25±8.23 |
第12个月 | |||||||
HLA全相合 | 20 | 57.76±9.76 | 21.92±5.42 | 31.99±10.05 | 0.72(0.53~0.95) | 27.14(20.29~36.07) | 13.70±6.57 |
HLA不全相合 | 7 | 69.82±12.37 | 24.10±8.21 | 43.34±15.58 | 0.46(0.30~1.14) | 11.62(7.33~25.24) | 13.86±4.76 |
统计值 | 0.004 | 0.958 | 0.084 | 60.000 | 35.000 | 1.017 | |
P值 | 0.948 | 0.330 | 0.772 | 0.580 | 0.053 | 0.316 |
组别 | 例数 | CD3+ T细胞 | CD3+CD4+ T细胞 | CD3+CD8+ T细胞 | CD4+/CD8+ 比值 | CD19+ B细胞 | CD16+CD56+ NK细胞 |
---|---|---|---|---|---|---|---|
术前 | |||||||
男童 | 16 | 71.68±8.43 | 38.33±8.59 | 29.11±12.70 | 1.48(1.36~1.80) | 18.32(11.28~24.09) | 10.64±3.29 |
女童 | 11 | 65.86±15.14 | 36.36±9.58 | 24.99±9.31 | 1.33(1.12~2.39) | 17.98(11.50~21.88) | 14.72±9.90 |
术后 | |||||||
第1个月 | |||||||
男童 | 16 | 73.01±15.72 | 15.78±9.20 | 53.80±18.19 | 0.33(0.17~0.42) | 1.17(0.50~12.69) | 19.96±9.23 |
女童 | 11 | 68.67±22.28 | 12.58±7.51 | 51.00±23.91 | 0.19(0.14~0.57) | 10.01(0.64~31.85) | 13.12±8.94 |
第2个月 | |||||||
男童 | 16 | 58.41±16.39 | 11.26±3.62 | 43.62±14.88 | 0.24(0.19~0.41) | 16.24(6.90~23.50) | 23.33±10.37 |
女童 | 11 | 54.33±17.86 | 11.91±7.83 | 38.77±16.65 | 0.24(0.13~0.50) | 24.63(2.72~35.76) | 22.03±11.57 |
第3个月 | |||||||
男童 | 16 | 54.04±16.48 | 11.81±3.90 | 38.51±13.99 | 0.29(0.23~0.44) | 17.59(11.30~41.29) | 20.63±6.24 |
女童 | 11 | 54.56±18.92 | 13.38±6.20 | 32.68±16.79 | 0.38(0.24~0.50) | 18.50(4.36~47.99) | 20.30±10.68 |
第6个月 | |||||||
男童 | 16 | 53.21±14.85 | 15.46±5.66 | 34.45±14.25 | 0.41(0.29~0.83) | 30.91(11.24~38.14) | 18.04±7.51 |
女童 | 11 | 55.37±14.30 | 16.91±6.53 | 34.83±14.43 | 0.48(0.31~0.92) | 29.85(10.45~35.72) | 16.87±7.74 |
第12个月 | |||||||
男童 | 16 | 62.74±9.63 | 22.66±6.63 | 36.34±11.75 | 0.70(0.44~0.99) | 21.99(14.42~27.95) | 13.75±4.57 |
女童 | 11 | 58.18±13.99 | 22.22±5.71 | 32.87±13.77 | 0.71(0.46~1.09) | 29.06(18.30~39.12) | 13.73±8.02 |
统计值 | 1.973 | 0.440 | 0.016 | 80.500 | 64.000 | 0.750 | |
P值 | 0.163 | 0.509 | 0.901 | 0.711 | 0.236 | 0.389 |
组别 | 例数 | CD3+ T细胞 | CD3+CD4+ T细胞 | CD3+CD8+ T细胞 | CD4+/CD8+ 比值 | CD19+ B细胞 | CD16+CD56+ NK细胞 |
---|---|---|---|---|---|---|---|
术前 | |||||||
男童 | 16 | 71.68±8.43 | 38.33±8.59 | 29.11±12.70 | 1.48(1.36~1.80) | 18.32(11.28~24.09) | 10.64±3.29 |
女童 | 11 | 65.86±15.14 | 36.36±9.58 | 24.99±9.31 | 1.33(1.12~2.39) | 17.98(11.50~21.88) | 14.72±9.90 |
术后 | |||||||
第1个月 | |||||||
男童 | 16 | 73.01±15.72 | 15.78±9.20 | 53.80±18.19 | 0.33(0.17~0.42) | 1.17(0.50~12.69) | 19.96±9.23 |
女童 | 11 | 68.67±22.28 | 12.58±7.51 | 51.00±23.91 | 0.19(0.14~0.57) | 10.01(0.64~31.85) | 13.12±8.94 |
第2个月 | |||||||
男童 | 16 | 58.41±16.39 | 11.26±3.62 | 43.62±14.88 | 0.24(0.19~0.41) | 16.24(6.90~23.50) | 23.33±10.37 |
女童 | 11 | 54.33±17.86 | 11.91±7.83 | 38.77±16.65 | 0.24(0.13~0.50) | 24.63(2.72~35.76) | 22.03±11.57 |
第3个月 | |||||||
男童 | 16 | 54.04±16.48 | 11.81±3.90 | 38.51±13.99 | 0.29(0.23~0.44) | 17.59(11.30~41.29) | 20.63±6.24 |
女童 | 11 | 54.56±18.92 | 13.38±6.20 | 32.68±16.79 | 0.38(0.24~0.50) | 18.50(4.36~47.99) | 20.30±10.68 |
第6个月 | |||||||
男童 | 16 | 53.21±14.85 | 15.46±5.66 | 34.45±14.25 | 0.41(0.29~0.83) | 30.91(11.24~38.14) | 18.04±7.51 |
女童 | 11 | 55.37±14.30 | 16.91±6.53 | 34.83±14.43 | 0.48(0.31~0.92) | 29.85(10.45~35.72) | 16.87±7.74 |
第12个月 | |||||||
男童 | 16 | 62.74±9.63 | 22.66±6.63 | 36.34±11.75 | 0.70(0.44~0.99) | 21.99(14.42~27.95) | 13.75±4.57 |
女童 | 11 | 58.18±13.99 | 22.22±5.71 | 32.87±13.77 | 0.71(0.46~1.09) | 29.06(18.30~39.12) | 13.73±8.02 |
统计值 | 1.973 | 0.440 | 0.016 | 80.500 | 64.000 | 0.750 | |
P值 | 0.163 | 0.509 | 0.901 | 0.711 | 0.236 | 0.389 |
[1] | 徐宏贵,方建培. 造血干细胞移植治疗β地中海贫血[J]. 中国实用儿科杂志,2014,29(11):818-822. |
[2] | 许吕宏,方建培. 儿童血液疾病研究进展[J]. 中国实用儿科杂志,2013,28(5):344-346. |
[3] | 张瀚文,朱宝生. 地中海贫血的治疗进展及预防[J]. 中国妇幼保健,2016,31(3):666-668. |
[4] | 李华晖. 重型地中海贫血患者同胞造血干细胞移植后移植物抗宿主病相关危险因素分析[D]. 南宁:广西医科大学,2017. |
[5] | LI C,WU X,FENG X,et al.A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation[J]. Blood,2012,120(19):3875-3881. |
[6] | OEVERMANN L,LANG P,FEUCHTINGER T,et al.Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation[J]. Ann N Y Acad Sci,2012,1266:161-170. |
[7] | 杨楠,谷振阳,高春记. 造血干细胞移植后自然杀伤细胞的重建及其临床意义[J]. 解放军医学院学报,2016,37(11):1186-1189. |
[8] | 谭亚敏. 异基因造血干细胞移植后急性移植物抗宿主病防治策略及其关键T细胞和细胞因子研究[D]. 杭州:浙江大学,2014. |
[9] | SCHLENKE P,SHEIKHZADEH S,WEBER K,et al.Immune reconstitution and production of intracellular cytokines in T lymphocyte populations following autologous peripheral blood stem cell transplantation[J]. Bone Marrow Transplant,2001,28(3):251-257. |
[10] | 卫蓓文,唐暐,彭奕冰,等. 全相合异基因造血干细胞移植后免疫重建的研究[J]. 检验医学,2014,29(9):925-929. |
[11] | WIDMER C C,BALABANOV S,SCHANZ U,et al.Transient paraproteinemia after allogeneic hematopoietic stem cell transplantation is an underexplored phenomenon associated with graft versus host disease[J]. Oncotarget,2017,8(63):106333-106341. |
[12] | DIETZ A C,WAYNE A S.Cells to prevent/treat relapse following allogeneic stem cell transplantation[J]. Hematology Am Soc Hematol Educ Program,2017,2017(1):708-715. |
[13] | 陈纯,魏菁,方建培,等. 同胞供者全相合脐血移植治疗重型β地中海贫血的细胞免疫重建分析[J]. 中国免疫学杂志,2008,24(10):896-898. |
[14] | 林遐. 异基因造血干细胞移植术后中枢T细胞免疫重建的初步研究[D]. 广州:南方医科大学,2015. |
[15] | 黄炎青,杨益莲,丁家华,等. 造血干细胞移植后患者淋巴细胞免疫重建的研究[J]. 现代医学,2015,43(6):732-736. |
[16] | 朱明霞,万文丽,李海申,等. 造血干细胞移植后的早期免疫重建[J]. 北京大学学报(医学版),2016,48(3):515-522. |
[1] | WANG Huiying, TANG Yu, DONG Lili, WANG Jing. Role of Mycoplasma pneumoniae RNA determination in diagnosis and efficacy monitoring of pneumonia in children [J]. Laboratory Medicine, 2023, 38(9): 865-869. |
[2] | SHI Yingying, PAN Fen, SUN Yan, WANG Chun, JIANG Jie, YU Fangyuan, ZHANG Tiandong, QIN Huihong, ZHANG Hong. Nested multiple polymerase chain reaction in rapid diagnosis of meningitis/encephalitis in children [J]. Laboratory Medicine, 2023, 38(8): 766-770. |
[3] | FU Limei, YANG Dan, XU Jin, ZHU Haiyan, ZHU Fenhua. Clinical significance of whole blood trace elements and serum vitamin levels in 6 common skin diseases in children [J]. Laboratory Medicine, 2023, 38(8): 771-775. |
[4] | ZHANG Xin, MA Lijuan. Role of cardiac markers in children [J]. Laboratory Medicine, 2023, 38(6): 505-509. |
[5] | YANG Qiong, XU Fen, LIN Yahui. Clinical application of cardiac troponin determination in pediatric cardiac involvement related diseases [J]. Laboratory Medicine, 2023, 38(6): 510-517. |
[6] | LI Li, SUN Haiyan, LI Yuanrui, DOU Min, TANG Wen, JIANG Limin, SHEN Lisong. Changes and clinical roles of perioperative NT-proBNP and PCT in children with congenital heart disease [J]. Laboratory Medicine, 2023, 38(6): 524-531. |
[7] | LIU Yanan, XIA Min, HU Shaohua, ZHENG Yue, ZHANG Hong. Roles of lymphocyte subsets,inflammatory factors and NT-proBNP in diagnosis of Kawasaki disease [J]. Laboratory Medicine, 2023, 38(6): 532-537. |
[8] | WANG Yaling, HUANG Yunli, TIAN Mi, WANG Shunlan, XIAO Li. Relationship between EOS%,CCR3,eotaxin and disease severity in children with acute bronchopneumonia [J]. Laboratory Medicine, 2023, 38(3): 230-234. |
[9] | WU Jinying, FANG Yulian, WANG Wei, HOU Mengzhu, WANG Lu, ZHAO Yu. Clinical characteristics and epidemiological of enterovirus infection in children with acute diarrhea in Tianjin [J]. Laboratory Medicine, 2023, 38(3): 267-271. |
[10] | ZHAO Yanhong, FU Lin, LIU Biao, XIAO Meifang. Reference interval of lactate dehydrogenase among 3-14-year-old population in Hainan [J]. Laboratory Medicine, 2023, 38(11): 1041-1043. |
[11] | HU Shaohua, CHEN Li, ZHAO Meng, MA Zhan, ZHANG Hong. Epidemiological characteristic analysis of Mycoplasma pneumoniae infection in children in Shanghai [J]. Laboratory Medicine, 2023, 38(1): 14-17. |
[12] | WEI Rui, YUAN Xu, TIAN Xuewen, LU Yanjun. Clinical and laboratory characteristics of human metapneumovirus infection children in a Grade A Class 3 hospital in Wuhan [J]. Laboratory Medicine, 2023, 38(1): 18-22. |
[13] | LU Lijuan, XU Jin. Thoughts on whether adenovirus is the cause of the hepatitis of unknown etiology among children recently [J]. Laboratory Medicine, 2022, 37(8): 705-709. |
[14] | TAN Meiyu, SHU Jie, XUAN Binbin, ZHOU Lida, LI Hong, HOU Shangwei, SHENG Huiming. Effects of SARS-CoV-2 vaccination on antibody production and immune function [J]. Laboratory Medicine, 2022, 37(8): 729-734. |
[15] | AO Jiajia, ZHANG Junfeng, NIE Wenjian, YE Qing. Relationship of fasting C-peptide with nonalcoholic fatty liver disease in children with obesity [J]. Laboratory Medicine, 2022, 37(7): 618-622. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||